Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Delos Capital is a prominent biotech venture capital firm founded in 2014 and headquartered in Cambridge, Massachusetts. With a mission to support innovative life sciences companies, Delos Capital focuses on addressing unmet medical needs through strategic investments. The firm has established a reputation for its deep understanding of biology and its commitment to advancing healthcare solutions. Since its inception, Delos Capital has raised multiple funds, although specific fund sizes and assets under management (AUM) are not publicly disclosed. The firm operates primarily in North America and Asia, allowing it to tap into diverse markets and innovative biotech ecosystems. Delos Capital's leadership team comprises experienced professionals with extensive backgrounds in life sciences, venture capital, and entrepreneurship, enabling them to provide valuable insights and guidance to their portfolio companies. Their strategic approach to investing is characterized by a thorough evaluation of scientific merit and market potential, ensuring that they partner with companies poised for significant advancements in healthcare.
Delos Capital specializes in investing in various sectors within the life sciences, including cardiometabolic, immunology, infectious disease, neurology, oncology, and rare diseases. The firm is committed to supporting companies at all stages of their development, from early-stage startups to more established firms seeking growth equity. Delos Capital's investment strategy is driven by a deep understanding of biology and the specific unmet medical needs within these therapeutic areas. They seek to partner with visionary founders and innovative companies that are dedicated to developing medical breakthroughs. The firm typically invests across a wide range of funding stages, including Friends and Family, Angel, Accelerator, Pre Seed, Seed, Seed Plus, Series A, Series B, Series C, Series D, Series E, and Growth Equity. This flexibility allows Delos Capital to engage with a diverse array of companies and support them throughout their growth journey, ultimately aiming to improve patient outcomes and advance healthcare solutions.
Delos Capital boasts a diverse and impressive portfolio of life sciences companies that are making significant strides in their respective fields. Notable investments include TRexBio, which is focused on developing next-generation therapies to restore immune homeostasis, and Zenas (NASDAQ: ZBIO), which is innovating therapeutics for inflammatory and immunology indications. Other key portfolio companies include Averna Therapeutics, which is working on mRNA-based genetic medicines; Eccogene, engaged in drug discovery for obesity and metabolic diseases; Syndax (NASDAQ: SNDX), known for its innovative cancer therapies; and Thermalin, a pioneer in next-generation insulin solutions. Additionally, Delos Capital has invested in companies such as Antios, Cardurion Pharmaceuticals, and Clover Biopharmaceuticals, further showcasing their commitment to supporting groundbreaking advancements in healthcare. The firm's strategic investments reflect a strong focus on addressing critical medical needs and enhancing patient care through innovative solutions.
To pitch Delos Capital, founders should prepare a detailed presentation that outlines their business model, market potential, and scientific innovations. While specific submission guidelines are not provided, a well-structured pitch is essential. Founders are encouraged to reach out through their official website for further instructions on the application process.
Delos Capital invests across a wide range of stages, including Friends and Family, Angel, Accelerator, Pre Seed, Seed, Seed Plus, Series A, Series B, Series C, Series D, Series E, and Growth Equity. This comprehensive approach allows them to support companies at various points in their development journey.
Delos Capital primarily focuses on the life sciences sector, with specific interests in cardiometabolic, immunology, infectious disease, neurology, oncology, and rare diseases. They seek to invest in companies that address unmet medical needs within these therapeutic areas.
Delos Capital operates in North America and Asia, allowing them to tap into diverse biotech ecosystems and innovative markets. This geographic focus enables them to identify and support promising life sciences companies across different regions.
While specific check sizes are not publicly disclosed, Delos Capital invests across various funding stages, which typically suggests a range of investment amounts tailored to the needs of the companies they support.
Founders interested in pitching Delos Capital should prepare a comprehensive presentation that outlines their business model, market potential, and scientific merit. While specific submission guidelines are not provided, a well-structured pitch that highlights the innovative aspects of the company is recommended.
Delos Capital offers valuable insights and guidance to its portfolio companies, leveraging their deep expertise in life sciences. They aim to support startups in navigating the complexities of the biotech landscape and achieving their growth objectives.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.